RespireRx Pharmaceuticals Inc (RSPI)

[enemem]

I think there's room for some ambiguity. Right now RD is the wall for anybody developing analgesics, and the only thing available to doctors now (in the context of opioids) is naloxone. If we get ok efficacy, then ampakines are an alternative to naloxone, and cannot have a worse anti-analgesia profile. BPs will recognize that a. this was a far-from-perfect trial design; b. there are other ampakines in the pipeline, with wiggle-room via better formulations, more accurate dosages, etc.

There's an aphorism in The Ginger Man: "Dear God give me one break that's not my neck"